Member Name: {{MEMFIRST}} {{MEMLAST}} DOB: {{MEMBERDOB}} PA Number: {{PANUMBER}}



## Koselugo

## **Prior Authorization Request**

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155. If you have questions regarding the prior authorization, please contact CVS Caremark at 1-866-814-5506. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect<sup>®</sup> 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do not call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: {{MEMFIRST}} {{MEMLAST}} Date: {{TODAY}} Patient's ID {{MEMBERID}} Patient's Date of Birth: {{MEMBERDOB}} Physician's Name: {{PHYFIRST}} {{PHYLAST}} Specialty:, NPI#: Physician Office Telephone: {{PHYSICIANPHONE}} Physician Office Fax: {{PHYSICIANFAX}} Request Initiated For: {{DRUGNAME}}	
1.	What is the diagnosis?  ☐ Neurofibromatosis type 1 ☐ Pilocytic Astrocytoma ☐ Langerhans cell histiocytosis ☐ Other
2.	What is the ICD-10 code?
3.	Is the patient currently receiving treatment with the requested medication? ☐ Yes ☐ No If No, skip to Diagnosis section.
4.	Is there evidence of unacceptable toxicity or disease progression while on the current regimen? ☐ Yes ☐ No No further questions
	ction A: Neurofibromatosis
5.	Does the patient have symptomatic, inoperable plexiform neurofibromas (PN)?
	etion B: Pilocytic Astrocytoma
6.	What is the clinical setting in which the requested medication will be used?  ☐ Recurrent disease ☐ Progressive disease ☐ Other
7.	Does the patient's disease have a BRAF fusion or BRAF V600E activation mutation? <i>ACTION REQUIRED:</i> **Please attach documentation of BRAF fusion or BRAF V600E mutation status.  □ Yes - BRAF fusion □ Yes - BRAF V600E activating mutation □ No - None of the above □ Unknown
8.	Will the requested medication be used as a single agent? ☐ Yes ☐ No
Sec	ction C: Langerhans Cell Histiocytosis
9.	Will the requested medication be used as a single agent? ☐ Yes ☐ No
	ttest that this information is accurate and true, and that documentation supporting this formation is available for review if requested by CVS Caremark or the benefit plan sponsor.
<b>X</b> _	
Pre	escriber or Authorized Signature Date (mm/dd/yy)

Send completed form to: Case Review Unit CVS Caremark Prior Authorization Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Koselugo SGM - 8/2023.